Nova Pharma gets National Institute of Biotechnology contract


PETALING JAYA: Nova Pharma Solutions Bhd (NPS) has accepted a letter of acceptance from the National Institutes of Biotechnology Malaysia (NIBM) to undertake equipment procurement and facility upgrade for NBIM’s national vaccine production development and enhancement programme.

In a filing with Bursa Malaysia, NPS said the project will take place at the Malaysia Genome and Vaccine Institute, which is located within NIBM's premises in Kajang, Selangor.

“The project will not have any effect on the share capital and shareholding structure of the company.

“The project is expected to contribute positively to earnings and net assets per share of NPS from the financial year ending Dec 31, 2024 until the completion of the project.”

NPS said it intends to carry out the project via internally generated funding and bank borrowings.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Nova Pharma

   

Next In Business News

F&N ends FY24 with higher net profit of RM542.77mil
Bursa Malaysia reverses early losses to end higher ahead of MPC outcome
Proton October sales up 13.6%, YTD hits 125,557 units
TCS secures RM86.38mil construction contract from Sime Darby Property
Oil trades in tight range ahead of US election
China shares jump, dollar skittish with all eyes on US Election Day
Bank Negara unveils key principles to harness Islamic finance for economic growth
Aneka Jaringan unit secures RM39mil contract for KL project
Xin Hwa says transport unit's vehicle operator licence suspended
T7 Global unit bags ExxonMobil contract

Others Also Read